

Company Overview

» Leading respiratory biotech

- Focused on developing novel and innovative drugs to treat respiratory diseases
- Unique multi-targeting approach against inflammation
- Leading company in the discovery & development of oligonucleotide drugs for respiratory diseases

» Advanced, innovative product portfolio

- Lead product in Phase 2 development
- Designed to address unmet clinical needs in asthma & COPD
- Targeting high growth, high value market segments

» Focused business strategy

- To advance compounds through Phase II studies, then partner for late-stage development and commercialization

Key Management

Mark Parry-Billings, PhD
Chief Executive Officer



Robert Boisjoli, CA
Chief Financial Officer



Lisa Nolan, PhD
Chief Business Officer



Paulo Renzi, MD
Founder and Chief Medical Officer



Key Investment Highlights

- Innovative, first-in-class products for COPD and asthma
- Positioned in high value, high growth market segments
- Opportunities to create high-impact partnerships with pharmaceutical and biotech companies
- Attractive position within a sector experiencing robust M&A interest
- Significant milestones in next 18 to 24 months
- Experienced management team with proven record in respiratory product development, in respiratory product licensing and successful financing, M&A and exit strategies


Board Members and Investors

Board is chaired by Gary Lessing (independent) and Board members representing investors including Jeremy Curnock Cook (Bioscience Managers), Chip Gillooly (NovaQuest), Charlie Fong (BDC) and Pierre Pharand (CDP Capital).


Dr. Mark Parry-Billings, CEO
mark.parry-billings@topigen.com
Tel: 514-868-0077 x241
Cell: 514-969-3991

Robert Boisjoli, CA, CFO
robert.boisjoli@topigen.com
Tel: 514-868-0077 x120
Cell: 514-821-9857

Therapeutic Markets



Asthma ~ \$14Billion
Key Unmet Need:
More effective treatment for moderate and severe asthma



COPD ~ \$10Billion
Key Unmet Need:
Effective anti-inflammatory to slow down disease progression

Pipeline

	Discovery	Pre-clinical	Phase 1	Phase 2	Phase 3
TPI ASM8 asthma	→				
TPI 1100 COPD	→				
Discovery Candidates	→				

Proprietary FANA Technology

TPI ASM8 Profile

- Inhaled anti-inflammatory
- Novel mechanism of action
- Indication: moderate/severe asthma
- Once daily dosing
- 73 patients dosed in one phase I and two phase II studies
- Clean safety profile
- Preliminary clinical proof of concept
- Robust formulation
- Path forward in phase IIa and toxicology program defined

TPI 1100 Profile

- Unique dual PDE 4/7 inhibitor
- Inhaled once-daily
- Indications: COPD / asthma
- Systemic exposure is minimal following inhalation; expect significant safety advantages vs. small molecule PDE inhibitors
- Significantly more potent than roflumilast in in vivo models for COPD